Despite limited clinical trials on SGLT-2 inhibitors or GLP-1 agonist monotherapy, these therapeutic agents have been investigated as new classes of antidiabetic drugs and are recommended as add-on therapies for treating patients with diabetes [36,37]. The gene discussed is SLC5A2; the disease is diabetes mellitus.